Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Graft Polymer (GPL)

Price 0.21p on 18-12-2024 at 14:00:08
Change 0.00p 0%
Buy 0.22p
Sell 0.20p
Buy / Sell GPL Shares
Last Trade: Buy 159,532.00 at 0.214p
Day's Volume: 4,670,753
Last Close: 0.21p
Open: 0.21p
ISIN: GB00BMD1Z199
Day's Range 0.21p - 0.21p
52wk Range: 0.087p - 1.15p
Market Capitalisation: £5m
VWAP: 0.205707p
Shares in Issue: 2,296m

Recent Trades History Graft Polymer (GPL)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 159,532 0.214p Ordinary
13:00:43 - 18-Dec-24
Unknown* 503,909 0.2008p Ordinary
08:00:41 - 18-Dec-24
Unknown* -503,909 0.20082p Ordinary
Correction
08:00:41 - 18-Dec-24
Unknown* 346,852 0.2008p Ordinary
08:00:09 - 18-Dec-24
Unknown* -346,852 0.20082p Ordinary
Correction
08:00:09 - 18-Dec-24
Sell* 160,460 0.209p Ordinary
11:41:38 - 18-Dec-24
Sell* 900,000 0.206p Ordinary
11:09:32 - 18-Dec-24
Sell* 2,600,000 0.2065p Ordinary
09:32:51 - 18-Dec-24
Sell* 503,909 0.20082p Ordinary
08:00:41 - 18-Dec-24
Sell* 346,852 0.20082p Ordinary
08:00:09 - 18-Dec-24

Share Price History for Graft Polymer

Time period:
to
Date Open High Low Close Volume

Share News for Graft Polymer

TRADING UPDATES: Strategic Minerals touts improved Cobre sales

15th Oct 2024 14:22

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

IN BRIEF: Graft Polymer selects Eurfins to test aminoindane series

4th Oct 2024 19:10

Graft Polymer (UK) PLC - London-based developer and producer of alloyed polymers, biological supplements and drug delivery systems - Selects drug discovery solutions provider Eurofins Discovery to carry out initial testing for its co-lead aminoindane series, to begin immediately. First announced in July, the programme is under joint development with Awakn Life Sciences Corp and seeks to develop next-generation medicines targeting trauma-related mental health conditions like Post-Traumatic Stress Disorder. The condition affects about 20 million adults in the US, UK, and key European markets, Graft Polymer notes. Tests will assess the potential of Graft's aminoindane series for serotonin, dopamine and noradrenaline reuptake inhibition. Selection marks a significant milestone, the company says, and follows its August announcement that it filed a new provisional patent in the US after Awakn "identified two aminoindane chemical series as co-leads for further development". Read More

Graft Polymer confident as biotech firm as loss narrows

13th Sep 2024 11:48

(Alliance News) - Graft Polymer UK PLC on Friday it was confident in its strategy as it reported a narrowed interim loss. Read More

TRADING UPDATES: Graft Polymer makes Awakn progress; ORIT Sweden deal

28th Aug 2024 18:31

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

EXECUTIVE CHANGES: New chief executives at Cornish Metals and ValiRx

12th Aug 2024 12:01

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced in August so far and not separately reported by Alliance News: Read More

FTSE 100 Latest
Value8,203.58
Change8.38

Login to your account

Forgot Password?

Not Registered